CMPS · COMPASS Pathways plc · Executive Compensation
$8.28
+0.16 (+1.97%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$1.15B
Shares
141.71M
Volume · Nov 19
152.13K
Avg daily vol (3M)
3.01M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Thomas Lönngren
“Mr. Lönngren’s decision to retire from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
director | Retired | 2025-10-29 |
| Jeff Jonas, M.D. | director | Appointed | 2025-10-29 |
|
Linda McGoldrick
“Dr. McGoldrick's decision to retire from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
position on the Board | Retired | 2025-07-29 |
| Justin Gover | Class III director | Appointed | 2025-07-29 |
| Gino Santini | director | Appointed | 2024-08-01 |
| Gino Santini | Chairman | Appointed | 2024-08-01 |
| David Norton | Chair of the Board | Appointed | 2024-03-28 |
|
Ekaterina Malievskaia
“Neither Mr. Goldsmith's nor Dr. Malievskaia's decision to resign was the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
board of directors | Resigned | 2024-03-28 |
|
George Goldsmith
“Neither Mr. Goldsmith's nor Dr. Malievskaia's decision to resign was the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
Chair of the Board | Resigned | 2024-03-28 |
| Teri Loxam | Chief Financial Officer (CFO) | Appointed | 2023-12-07 |
| Mary-Rose Hughes | Interim Chief Financial Officer | Appointed | 2023-10-26 |
|
Michael Falvey
“Mr. Falvey’s resignation was not due to any disagreement with the Company on any matter, including related to the Company’s operations, policies, practices, financial reporting, accounting matters or internal controls.”
|
Chief Financial Officer, principal financial officer and principal accounting officer | Resigned | 2023-10-26 |
| Daphne Karydas | Class III director | Appointed | 2023-09-18 |
| Dr. Ekaterina Malievskaia | Chief Innovation Officer | Terminated | 2023-05-31 |
| George Goldsmith | executive chairman | Appointed | 2022-07-19 |
| Kabir Nath | Class II director | Appointed | 2022-07-19 |
| Kabir Nath | chief executive officer | Appointed | 2022-07-19 |
| Jason Camm | director | Retired | 2022-04-21 |
Leadership
- Kabir Nath CEO, Board Member
- David Norton Chairman, Board Member
- George Goldsmith Chairman
- Gino Santini Chairman, Board Member
- Mary-Rose Hughes CFO, Chief Accounting Officer
- Teri Loxam CFO
- Matthew Owens General Counsel
- Annalisa Jenkins Board Member
- Daphne Karydas Board Member
- Jeff Jonas, M.D. Board Member
- Jeffrey Jonas Board Member
- Justin Gover Board Member
- Robert McQuade Board Member
- Wayne Riley Board Member
Key facts
CIK
1816590
CUSIP
20451W101
13F (30d)
225 filings
216 filers
Visit website
Investor relations